[Drug therapy of type 2 diabetes and cardiovascular prevention: potentials for liraglutide].

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Giornale italiano di cardiologia

• Publication date

  2009-07-01

• Fields of study

  Medicine

• Identifiers
  PMID 19761101
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• WITHDRAWN: Metformin monotherapy for type 2 diabetes mellitus.

  2015cited by this paper
• Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD) (Diabetes Care (2009) 32, (1224-1230))

  2010cited by this paper
• Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials.

  2010cited by this paper
• Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.

  2010cited by this paper
• Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials

  2009cited by this paper
• Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

  2009cited by this paper
• Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.

  2009cited by this paper
• GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice

  2009cited by this paper
• Effects of Prandial Versus Fasting Glycemia on Cardiovascular Outcomes in Type 2 Diabetes: The HEART2D trial

  2009cited by this paper
• Treatment of type 2 diabetes with incretin-based therapies.

  2009cited by this paper
• Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy

  2009cited by this paper
• Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population‐based follow‐up study

  2009cited by this paper
• Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

  2009cited by this paper
• Liraglutide: a new treatment for type 2 diabetes.

  2009cited by this paper
• Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue.

  2009cited by this paper
• Standards of medical care in diabetes--2007.

  2009cited by this paper
• Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials

  2008cited by this paper
• Oral antidiabetic medication adherence and glycemic control in managed care.

  2008cited by this paper
• Unmet needs among patients with Type 2 diabetes and secondary failure to oral anti-diabetic agents

  2008cited by this paper
• Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension.

  2008cited by this paper
• Beyond the Era of NPH Insulin—Long-Acting Insulin Analogs: Chemistry, Comparative Pharmacology, and Clinical Application

  2008cited by this paper
• DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?

  2008cited by this paper
• Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension.

  2008cited by this paper
• Metformin: Effects on Micro and Macrovascular Complications in Type 2 Diabetes

  2008cited by this paper
• 10-year follow-up of intensive glucose control in type 2 diabetes.

  2008cited by this paper
• Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy

  2008cited by this paper
• Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis.

  2008cited by this paper
• New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond.

  2008cited by this paper
• DIABETICMedicine Blackwell Publishing Ltd Original Article: Complications DOI: 10.1111/j.1464-5491.2009.02667.x Reliability and validity of the modified Toronto Clinical Neuropathy Score in diabetic sensorimotor

  2008cited by this paper
• Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes

  2008cited by this paper
• Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.

  2008cited by this paper
• Mechanisms of ENaC regulation and clinical implications.

  2008cited by this paper
• Exercise or exercise and diet for preventing type 2 diabetes mellitus.

  2008cited by this paper
• Time course of AQP-2 and ENaC regulation in the kidney in response to PPAR agonists associated with marked edema in rats.

  2008cited by this paper
• Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

  2008cited by this paper
• Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes.

  2008cited by this paper
• Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes

  2008cited by this paper
• Effects of intensive glucose lowering in type 2 diabetes.

  2008cited by this paper
• Barriers to Medication Adherence in Poorly Controlled Diabetes Mellitus

  2008cited by this paper
• La terapia del diabete di tipo 2 basata su glucagon-like peptide-1 e farmaci correlati: effetti pleiotropici sul sistema cardiovascolare

  2008cited by this paper
• Intensive insulin therapy in newly diagnosed type 2 diabetes.

  2008cited by this paper
• Italian standards for diabetes mellitus 2007: executive summary

  2008cited by this paper
• New Drugs for the Treatment of Diabetes Mellitus: Part I: Thiazolidinediones and Their Evolving Cardiovascular Implications

  2008cited by this paper
• Recurrence of Cardiovascular Events in Patients With Type 2 Diabetes

  2008cited by this paper
• UKPDS and the legacy effect.

  2008cited by this paper
• Thiazolidinediones in Type 2 Diabetes: A Cardiology Perspective

  2008cited by this paper
• Rosiglitazone - : Continued uncertainty about safety

  2007cited by this paper
• Medication Taking and Diabetes

  2007cited by this paper
• MI risks linked to rosiglitazone.

  2007cited by this paper
• Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary

  2007cited by this paper
• Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.

  2007cited by this paper
• Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.

  2007cited by this paper
• Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.

  2007cited by this paper
• Rosiglitazone for type 2 diabetes mellitus.

  2007cited by this paper
• Meglitinide analogues for type 2 diabetes mellitus.

  2007cited by this paper
• Paradoxical HDL‐C reduction during rosiglitazone and fibrate treatment

  2007cited by this paper
• A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes

  2007cited by this paper
• Uncertain Effects of Rosiglitazone on the Risk for Myocardial Infarction and Cardiovascular Death

  2007cited by this paper
• Exenatide effects on statin pharmacokinetics and lipid response.

  2007cited by this paper
• Coronary heart disease outcomes in patients receiving antidiabetic agents

  2007cited by this paper
• Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.

  2007cited by this paper
• Rosiglitazone and cardiotoxicity--weighing the evidence.

  2007cited by this paper
• 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension.

  2007cited by this paper
• Rosiglitazone and the FDA.

  2007cited by this paper
• Rosiglitazone and cardiovascular risk.

  2007cited by this paper
• The rosiglitazone story--lessons from an FDA Advisory Committee meeting.

  2007cited by this paper
• Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.

  2007cited by this paper
• Insulin‐associated weight gain in diabetes – causes, effects and coping strategies

  2007cited by this paper
• Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

  2007cited by this paper
• Five Weeks of Treatment with the GLP-1 Analogue Liraglutide Improves Glycaemic Control and Lowers Body weight in Subjects with Type 2 Diabetes

  2006cited by this paper
• Genome-wide identification of peroxisome proliferator response elements using integrated computational genomics s⃞ Published, JLR Papers in Press, April 3, 2006.

  2006cited by this paper
• The place of sulfonylureas in the therapy for type 2 diabetes mellitus.

  2006cited by this paper
• Sulfonylureas and the risk of myocardial infarction.

  2006cited by this paper
• Is insulin resistance atherogenic? A review of the evidence.

  2006cited by this paper
• Drug interactions with lipid‐lowering drugs: Mechanisms and clinical relevance

  2006cited by this paper
• An Open‐Label, Parallel Group Study Investigating the Effects of Age and Gender on the Pharmacokinetics of the Once‐Daily Glucagon‐Like Peptide‐1 Analogue Liraglutide

  2006cited by this paper
• Pioglitazone for type 2 diabetes mellitus.

  2006cited by this paper
• Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose.

  2006cited by this paper
• Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.

  2005cited by this paper
• Diabetes and cardiovascular disease: the road to cardioprotection

  2005cited by this paper
• Drug Interactions of Clinical Importance with Antihyperglycaemic Agents

  2005cited by this paper
• Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

  2005cited by this paper
• Long-term non-pharmacological weight loss interventions for adults with prediabetes.

  2005cited by this paper
• Effects of liraglutide (NN2211), a long‐acting GLP‐1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes

  2005cited by this paper
• Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption

  2005cited by this paper
• Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.

  2005cited by this paper
• Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus.

  2005cited by this paper
• Metformin's contraindications should be contraindicated

  2005cited by this paper
• Alpha-glucosidase inhibitors for type 2 diabetes mellitus.

  2005cited by this paper
• Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.

  2005cited by this paper
• Angiotensin-Converting Enzyme Inhibitors and Calcium Channel Blockers for Coronary Heart Disease and Stroke Prevention

  2005cited by this paper
• Oral Antidiabetic Therapy in Patients with Heart Disease

  2004cited by this paper
• Insulin therapy and hypoglycaemia: the size of the problem

  2004cited by this paper
• The incidence of congestive heart failure in type 2 diabetes: an update.

  2004cited by this paper
• Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol.

  2004cited by this paper
• Acarbose Slows Progression of Intima-Media Thickness of the Carotid Arteries in Subjects With Impaired Glucose Tolerance

  2004cited by this paper
• Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful Reperfusion

  2004cited by this paper
• The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes.

  2004cited by this paper
• Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.

  2004cited by this paper
• Rosiglitazone Improves, While Glibenclamide Worsens Blood Pressure Control in Treated Hypertensive Diabetic and Dyslipidemic Subjects via Modulation of Insulin Resistance and Sympathetic Activity

  2004cited by this paper

• No citing papers are available for this paper.